Oppenheimer reiterates Outperform on Relay Therapeutics (RLAY) as zovegalisib shows 11.1-month PFS
Tweet Send to a Friend
Oppenheimer analyst Matt Biegler reiterated an Outperform rating and $14.00 price target on Relay Therapeutics (NASDAQ: RLAY)The analyst commented, "Relay ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
